2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12B.11 Clinical Treatment Selected by Patient-Derived Organoid in a Patient with Stage IV Lung Adenocarcinoma with Unique ALK Alternation

EP.12B.11 Clinical Treatment Selected by Patient-Derived Organoid in a Patient with Stage IV Lung Adenocarcinoma with Unique ALK Alternation

Back to course

Pdf Summary

The document details a study involving the use of patient-derived organoids (PDOs) to determine personalized treatment strategies for a patient with stage IV lung adenocarcinoma, characterized by a unique combination of ALK translocations and mutations. ALK (anaplastic lymphoma kinase) fusion is found in 3-5% of non-small cell lung cancers (NSCLC) and serves as a significant molecular target for treatment. The patient’s cancer featured a combination of EML4-ALK and NBAS-ALK translocations, alongside ALK 1171N and ALK 1171S mutations—a complex scenario that presents uncertainty regarding the efficacy of common ALK tyrosine kinase inhibitors (ALK-TKIs).<br /><br />By establishing a PDO model reflecting the patient's tumor, the researchers were able to perform drug sensitivity testing. This predictive approach was found to be consistent with the patient’s clinical response, suggesting that PDOs maintained the genetic and histopathological characteristics of the original tumor tissue. The study’s results support the potential of PDOs as valuable tools for personalizing cancer treatment, providing insights into drug effectiveness before clinical application.<br /><br />The findings underscore the importance of PDOs in developing precise treatment plans and predicting clinical outcomes for patients with lung cancer exhibiting unique genetic profiles. Ultimately, the study proposes PDOs as effective preclinical models that could revolutionize treatment personalization for complex cancer cases, enhancing prognosis and treatment precision for patients with unique ALK alterations in lung adenocarcinoma.

Asset Subtitle

Xiaoling Xu

Meta Tag

Speaker Xiaoling Xu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

patient-derived organoids

personalized treatment

stage IV lung adenocarcinoma

ALK translocations

ALK mutations

EML4-ALK

NBAS-ALK

drug sensitivity testing

cancer treatment personalization

preclinical models